WO2009012871A2 - Capsule filtrant les uv - Google Patents

Capsule filtrant les uv Download PDF

Info

Publication number
WO2009012871A2
WO2009012871A2 PCT/EP2008/005408 EP2008005408W WO2009012871A2 WO 2009012871 A2 WO2009012871 A2 WO 2009012871A2 EP 2008005408 W EP2008005408 W EP 2008005408W WO 2009012871 A2 WO2009012871 A2 WO 2009012871A2
Authority
WO
WIPO (PCT)
Prior art keywords
filter
sparingly soluble
soluble organic
triazine
phase
Prior art date
Application number
PCT/EP2008/005408
Other languages
German (de)
English (en)
Other versions
WO2009012871A3 (fr
Inventor
Frank Pfluecker
Bernd Mueller
Gabriele Witte
Valerie Andre
Original Assignee
Merck Patent Gmbh
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Basf Se filed Critical Merck Patent Gmbh
Priority to US12/670,442 priority Critical patent/US20100209463A1/en
Priority to KR1020107004187A priority patent/KR101529341B1/ko
Priority to ES08773820.9T priority patent/ES2522909T3/es
Priority to EP08773820.9A priority patent/EP2170253B1/fr
Priority to JP2010517286A priority patent/JP2010534623A/ja
Priority to CN2008801004407A priority patent/CN101795662B/zh
Priority to BRPI0814313A priority patent/BRPI0814313B1/pt
Publication of WO2009012871A2 publication Critical patent/WO2009012871A2/fr
Publication of WO2009012871A3 publication Critical patent/WO2009012871A3/fr
Priority to US15/395,013 priority patent/US20170105910A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/411—Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966—Triazines or their condensed derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • the present invention relates to UV filter capsules, their use for the preparation of cosmetic or dermatological formulations or dispersions and cosmetic or dermatological formulations containing the capsules, and to processes for their preparation.
  • UVC range UVC range
  • Ozone layer are absorbed in the earth's atmosphere, causing rays in the range between 290 nm and 320 nm, the so-called UVB range, erythema, a simple sunburn or even more or less severe burns.
  • UVA range Radiation in the range between about 320 nm and 400 nm (UVA range) has also been shown to cause damage to the elastic and collagen fibers of the connective tissue, prematurely aging the skin. Furthermore, these rays are the cause of numerous phototoxic and photoallergic reactions. The damaging effect of UVB radiation can be exacerbated by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products intervene in the skin metabolism.
  • UV radiation counts as ionizing radiation.
  • ionic species may also be formed on exposure to UV radiation, which in turn may oxidatively interfere with the biochemical processes.
  • UVA or UVB filters The light protection filters used today in cosmetics and dermatology are therefore also subdivided into UVA or UVB filters.
  • numerous compounds are known which are mostly derivatives of 3-Benzylidencamphers (eg Eusolex® 6300), 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone, triazine and also of 2-phenylbenzimidazole.
  • Dibenzoylmethane derivatives are frequently used to protect against UVA radiation, such as, for example, 4- (tert-butyl) -4'-methoxy-dibenzoylmethane (Eusolex® 9020) or 4-isopropyldibenzoylmethane (Eusolex® 8020) UV irradiation are not unlimitedly stable.
  • the provision of cosmetic products having improved, more effective or optimized protection of the human skin from the damaging effects of UV-A and UV-B radiation is of great importance. It is particularly desirable to provide preparations which achieve the desired effect with the lowest possible use of the individual components.
  • the specific extinction of the light stabilizers play a role as well as the stability of the emulsions prepared with them, their toxicological safety and their solubility in the carriers used (for example cosmetic oils). Some of the light stabilizers used so far are characterized by good extinction properties, but the low solubility of these
  • UV filter Uvinul ® T150 features (INCI: Ethylhexyltriazone) excellent UV absorption properties, but these UV filters can be solved in cosmetic oils limited and can in a number of
  • Formulations are incorporated only in relatively small proportions, whereby the protection factor to be achieved by this filter is limited.
  • a water-soluble or dispersed dosage form does not yet exist for ethylhexyl triazone. It has now been found that sparingly soluble organic UV filters can be used excellently in encapsulated form if the capsule contains an emollient capable of dissolving the poorly soluble organic UV filter at greater than 40% by weight at 25 ° C. to solve.
  • a first subject of the present invention are therefore UV filter capsules containing a polymeric shell and a) at least one sparingly soluble organic UV filter and b) an emollient capable of being heated at room temperature (20 ° to 25 ° C.) to solve more than 40 wt .-% of the sparingly soluble organic UV filter.
  • Suitable capsules may comprise walls of inorganic or organic polymers.
  • US Pat. No. 6,242,099 B1 describes the preparation of suitable capsules with walls or a shell of chitin, chitin derivatives or polyhydroxylated polyamines.
  • Capsules which are particularly preferred for use according to the invention have walls or a shell which are produced by a sol-gel process, as described in applications WO 00/09652, WO 00/72806, WO 00/71084, WO 03/39510 and WO 03 / 066209, can be obtained or can be obtained.
  • capsules whose walls or shells are or are constructed of silica gel (silica, undefined silicon oxide hydroxide) are preferred here.
  • the production of such capsules is known to the person skilled in the art, for example, from the cited patent applications, the contents of which are expressly also part of the subject of the present application.
  • Preferably used capsules therefore consist of a shell and a core.
  • step a) an oil-in-water emulsion is prepared from a mixture containing a sol-gel precursor to make the polymeric shell, at least one sparingly soluble UV filter and an emollient capable of room temperature (20 0 C to 25 ° C) more than 40 wt .-% of the sparingly soluble organic UV filter to solve, in an aqueous
  • step b) the emulsion prepared in step a) is mixed to an aqueous solution having a pH of 2 to 4, preferably from 3 to 4, and optionally in step c) reaction products are separated from the sol-gel precursor ,
  • the aqueous solution from step b) serves primarily to accelerate the underlying condensation polymerization reaction, which causes the structure of the shell.
  • the resulting capsules can be isolated by means which are familiar to the expert. For example, they can be centrifuged or filtered. A particularly preferred type of insulation is spray drying. That is, in step c), in addition to the separation of the reaction products from the sol-gel precursor, if necessary, the UV filter capsules can be isolated.
  • a dispersion or suspension is obtained containing the UV filter capsules according to the invention in a form which can be used directly in cosmetic or dermatological preparations.
  • a re-suspension of the isolated capsules in, for example, deionized water or in another medium is conceivable and suitable for use in the preparations according to the invention.
  • the hydrophobic solution from step a) and also the aqueous solutions from step a) and b) may contain surfactants and / or other additives which can improve or even stabilize this process and / or the product.
  • sol-gel precursor there may be used a metal or semimetal alkoxide monomer, a metal ester, a half metal ester or a partially hydrolyzed and partially condensed polymer, or a mixture thereof.
  • Suitable and preferred sol-gel precursors are compounds of the formula M (R) n (P) m, in which M is a metal or semimetal, preferably Si 1 R is a hydrolyzable substituent and n is an integer from 2 to 4, P is a non- polymerizable substituent and m is an integer of 0 to 4, or a partially hydrolyzed or partially condensed polymer thereof or any mixture thereof.
  • tetraethyl orthosilicate or a partially hydrolyzed or partially condensed polymer thereof or a mixture thereof in the method described above.
  • Very particular preference is given to using tetraethyl orthosilicate as the sol-gel precursor. Further details are disclosed in the embodiments.
  • “Slightly soluble organic UV filters” in the sense of the present invention organic UV filter having a solubility in Dicaprylyl Carbonate (trade name Cetiol ® CC, Cognis) of less than 25%, 26%, 27%, 28 or 30%, preferably less than 31%, 32%, 33%, 34% or 35%, more preferably less than 36%, 37%, 38%, 39% or 40% at room temperature (2O 0 C to 25 ° C) and a test duration of 24 hours.
  • Dicaprylyl Carbonate trade name Cetiol ® CC, Cognis
  • the at least one sparingly soluble organic UV filter mentioned under a) is a Triazine derivative, Diarylbutadienderivat, Hydroxybenzophenonderivat and / or methylene bis-benzotriazolyl-tetramethylbutylphenolderivat.
  • 2,4,6-tris [3 'benzotriazol-2-yl) -2' -hydroxy-5 '-tert-octyl) phenylamino] -s-triazine are preferred.
  • the triazine derivatives are 2,4, 6- tris [anilino (p-carbo-2 '-ethyl-1' -hexyloxy)] - 1, 3,5-triazine (Uvinul T150 ®, BASF Aktiengesellschaft, according to INCI ethylhexyl Triazone) (dioctyl UV Sorb- HEB ® , 3V Sigma) and Bis-
  • 15-Ethylhexyloxyphenol methoxyphenyltriazin (Anisotriazine or Tinosorb S ®, Ciba-Geigy).
  • Very particularly preferred compounds are 2,4,6-tris [anilino (p-carbo-2 '-ethyl-1' -hexyloxy)] - 1, 3,5-triazine (Uvinul®T150, BASF Aktiengesellschaft) and / or dioctylbutamido-triazone (UV-Sorb-HEB®, 3V Sigma).
  • R 4 and R 5 are independently H, C- ⁇ -C 2 o-alkyl, C 3 -C 0 - ou
  • 0 cycloalkenyl preferably. Particularly preferred is the compound 1, 1-dicarboxy (2 ', 2-dimethylpropyl) -4-4- diphenyl butadiene.
  • the above-mentioned 4,4-diarylbutadienes are known as such and their structure and preparation are described in the patent applications EP 0967200 and EP 916 335, the contents of which are hereby incorporated by reference.
  • R 1 and R 2 are independently H, Ci-C 2 -alkyl, C 3 -C 10 - cycloalkyl or C 3 -C mean 10 cycloalkenyl wherein the substituents R 1 and R 2 together with the nitrogen atom to which they are bonded, can form a 5- or 6-membered ring and R 3 is C 1 -C 2 o-alkyl, preferably. More preferably, the 2- (4-N, N-diethylamino-2-hydroxybenzoyl) benzoic acid hexyl ester (Uvinul A Plus ®, BASF Aktiengesellschaft) is. Further examples of hydroxybenzophenones and their preparation can be found in the German patent application DE-A 11917906, the content of which is hereby incorporated by reference.
  • Alkyl radicals for substituents of the formulas II or III are branched or unbranched C 1 -C 20 -alkyl chains, preferably methyl, ethyl, n-propyl,
  • Alkenyl radicals for substituents of the formulas II or III are branched or unbranched C 2 -C 10 -alkenyl chains, preferably vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 2-methyl-1-butenyl , 2-methyl-2-butenyl, 3-methyl-1-butenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, 2-heptenyl, 1-octenyl or 2-octenyl.
  • Preferred cycloalkyl radicals for substituents of the formulas II or III are branched or unbranched C 3 -C 1 ( cycloalkyl chains such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-methylcyclopropyl, 1-ethylcyclopropyl, 1-propylcyclopropyl, 1-butylcyclopropyl .
  • cycloalkenyl radicals for substituents of the formulas II or III are preferably branched or unbranched, C 3 -Cio-cycloalkenyl chains having one or more double bonds such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1, 3-cyclohexadienyl, 1, 4-cyclohexadienyl, cycloheptenyl Cycloheptatrienyl, cyclooctenyl, 1,5-cyclooctadienyl, cyclooctatetraenyl, cyclononenyl or cyclodecyl.
  • the UV filter capsules according to the invention contain mixtures of the above-mentioned poorly soluble UV filters. 5
  • the UV filter capsules according to the invention contain as emollient compounds of the formula I,
  • the number "n” is an integer from 3 to 11, preferably from 4 to 10, more preferably from 5 to 9, most preferably from 6 to 8.
  • the compound of the general formula I is N, N-dimethyldecanamide (CAS # 14433-76-2), most preferably Spectrasolv DMDA (Jiangsu Feixang Chemicals).
  • Spectrasolv DMDA is particularly an excellent emollient for
  • Ethylhexyl triazone since its solubility at room temperature (20 0 C to 25 ° C) is about 55 wt .-%. Because of this excellent solubility, it is possible for the first time to produce UV filter capsules whose content of
  • Ethylhexyl triazone stands out clearly from the salaries obtained for the Zo hitherto on the market good solvent for ethylhexyl triazone. A list in this regard is given in the embodiments.
  • the UV filter capsules according to the invention usually contain 1
  • the core of the UV filter capsules according to the invention preferably comprises from 1 to 90% by weight, preferably from 5 to 70% by weight and particularly preferably from 40 to 60% by weight, of the at least one sparingly soluble organic UV filter, according to the invention the further
  • the capsule content is usually more than 40 wt .-% of the sparingly soluble organic UV-filter to disengage from the emollient, which is able at room temperature (20.degree 0 C to 25 ° C) and optionally other excipients, the solubility of the organic UV Filter further increase or stabilize exists.
  • the capsule content of the capsules according to the invention ie the core, preferably consists of the at least one organic sparingly soluble UV filter and the emollient, mixtures of organic sparingly soluble UV filters as described above and the emollient or mixtures of at least one sparingly soluble organic UV filter and soluble organic UV filter in the emollient, which is capable of dissolving at room temperature (20 0 C to 25 0 C) the sparingly soluble organic UV filter greater than 40 wt .-%.
  • the core consists of ethylhexyl triazone and N, N-dimethyldecanimide.
  • the UV filter capsules according to the invention are further characterized in that the core or capsule contents of the UV filter capsule mentioned under a) at least one sparingly soluble UV filter and under b) emollient in the weight percentage ratio 10:90 to 90:10 , preferably in the weight percent ratio 30:70 to 70:30, more preferably in the weight percent ratio of 40:60 to 60:40 or most preferably in the weight percent ratio of 50:50, contains or consists thereof.
  • the encapsulation provides the following advantages:
  • the hydrophilicity of the capsule wall (or synonymously the polymeric shell) can be adjusted independently of the solubility of the UV filter. Therefore, the sparingly soluble organic UV filters can be incorporated into purely aqueous formulations. As a result, the organic sparingly soluble organic UV filter can be incorporated as a final product both in the oil and in the water phase of the cosmetic or dermatological preparation. This can increase the overall content in cosmetic formulations. , If a poorly soluble UV filter is present in the organic phase and the poorly soluble UV filter encapsulated according to the invention is present in the aqueous phase, a so-called "boost effect" is observed.
  • a synergy occurs, or in other words, a "boost" when the same poorly soluble UV filter is present in the organic phase and encapsulated in the water phase, documentable by in vivo SPF values of formulations with no sparingly soluble ultraviolet filter encapsulated in accordance with the present invention this.
  • encapsulation of individual UV filters or other ingredients formulation problems caused by interaction of individual formulation components with each other, such as crystallization processes, precipitation and agglomeration can be avoided because the interaction is suppressed.
  • the selective selection of the particular emollient, in particular the selection of N, N-dimethyldecanamide (Spectrasolv DMDA) allows the solubility of the at least one sparingly soluble organic UV filter, as described above, in particular of ethylhexyl triazone, to remain constant during encapsulation the UV filter does not crystallize and thus a high loading of the capsule is possible.
  • the system described is furthermore temperature-stable, so that even during the possible temperature fluctuations during production, a stable capsule is created.
  • the sparingly soluble UV filter encapsulated according to the invention and usable in the water phase of a preparation may comprise the aqueous UV filters customary in the aqueous phase, for example
  • Phenylbenzimidazolesulfonic advantageously replace, since this eliminates the necessary pH regulation to arrive at stable preparations.
  • the proportion of the UV filter capsules according to the invention, as described above, in a dispersion at 5 to 80 wt .-%, particularly preferably from 30 to 70 wt .-%, most preferably from 35 to 45 wt .-% , based on the total amount of the dispersion.
  • the water content of the dispersions described is given at about 60% by weight.
  • Another object of the invention is the use of the UV filter capsules according to the invention, as described above, or a dispersion containing the UV filter capsules, as described above and below, for the preparation of a preparation, in particular a cosmetic or dermatological preparation.
  • Another object of the invention is a dispersion or suspension containing the UV filter capsules according to the invention, as described above.
  • this dispersion is an aqueous dispersion, i. the dispersing medium is water.
  • Dispersing media may also be any other suitable substances. Particularly suitable are polyhydric alcohols, e.g. Glycerol or 1,2-propanediol.
  • the dispersing medium may also be a suitable mixture, e.g. a glycerol-water mixture in any ratio.
  • predispersions which, on the one hand, are themselves suitable directly as a cosmetic or dermatological preparation and for Others may facilitate the preparation of such preparations containing a carrier.
  • the carrier is suitable for topical purposes, ie for a local, in particular superficially applicable form suitable.
  • the predispersions according to the invention can be incorporated into the water phase of each preparation, in particular into a cosmetic or dermatological preparation.
  • Another object of the invention is therefore a preparation containing at least one sparingly soluble organic UV filter and at least one suitable carrier, in particular a carrier suitable for topical use, characterized in that at least a portion of the sparingly soluble organic UV filter is encapsulated and in encapsulated Shape, as described for the UV filter capsules according to the invention.
  • UV filter capsules according to the invention are present in the aqueous phase, and at the same time in the oil phase at least one further oil-soluble or already in the poorly soluble UV filters present in the capsules, in particular the sparingly soluble UV filters, such as, for example, 2,4,6-tris [anilino (p-carbo-2'-ethyl-1'-hexyloxy)] - 1, 3,5- triazine, 2- (4-diethylamino-2-hydroxybenzoyl) -benzoic acid hexyl ester, 1, 1-dicarboxy (2 ', 2'-dimethylpropyl) -4-4-diphenylbutadiene or bis-ethylhexyloxyphenol-methoxyphenyltriazine.
  • 2,4,6-tris [anilino (p-carbo-2'-ethyl-1'-hexyloxy)] - 1, 3,5- triazine, 2- (4-diethylamino-2
  • the preparation may comprise or contain, consist essentially of or consist of the said necessary or optional constituents or ingredients. All connections or
  • Components that can be used in the preparations are either known and commercially available or can be synthesized by known or described methods.
  • preparation is used synonymously with the term formulation or agent.
  • Skin cosmetic, hair cosmetic, dermatological, hygienic or pharmaceutical compositions, preparations and / or formulations for topical application to the skin or hair are suitable (i) for the prevention of damage to human skin and / or human hair, (ii) for the treatment of damage already occurred human skin and / or human hair; (iii) care of human skin and / or human hair; (iv) improvement of skin feel (sensory properties).
  • Explicitly included are cosmetics for decorative cosmetics.
  • the preparations according to the invention are particularly preferably preparations for protecting the skin from damage by sunlight, in particular by UV-B (280 to 320 nm) and UV-A radiation (> 320 nm).
  • UV-B 280 to 320 nm
  • UV-A radiation > 320 nm
  • auxiliaries and additives which are chosen with regard to the specific field of application.
  • auxiliaries and additives are familiar to the expert and can be, for example, manuals of cosmetics, such as Schrader, bases and formulations of cosmetics, Weghig Verlag, Heidelberg, 1989, ISBN 3-7785-1491-1, or Umbach, cosmetics: development, manufacture and Application of cosmetic products, 2nd extended edition, 1995, Georg Thieme Verlag, ISBN 3 13 712602 9, be removed.
  • a process for producing a preparation, in particular a cosmetic or dermatological preparation with light protection properties is characterized in that the capsules according to the invention with further Ingredients are mixed.
  • a process for the preparation of a preparation, in particular a cosmetic or dermatological preparation with light protection properties is characterized in that a predispersion containing the capsules according to the invention is mixed with further ingredients.
  • a special process for the preparation of a preparation, in particular a cosmetic or dermatological preparation, in the form of an oil-in-water emulsion is characterized in that the predispersion described above is emulsified with an oil.
  • the capsules in formulations according to the invention are preferably present in amounts which ensure that the encapsulated UV filters are present in the formulation in effective amounts.
  • UV filter capsules according to the invention are preferably from 1 to 40% by weight, particularly preferably from 5 to 30
  • Wt .-% most preferably from 5 to 20 wt .-%, based on the total amount of the preparation.
  • the size of the UV filter capsules according to the invention can vary from 0.001 to 20.0 microns, the average particle size d (0.50), determined by a particle size determination by laser diffraction according to ISO / DIS 13320, usually at 200 to 5000 nm, preferably at 400 to 1500 nm. The method is described in the execution section.
  • compositions in particular the cosmetic or dermatological preparations, preferably with
  • Light protection properties can be in various forms. So they can z.
  • a water-in-oil (W / O) or oil-in-water (O / W) type solution emulsion or microemulsion, a multiple emulsion, such as Waser-in-oil-in type.
  • Water (W / O / W) a gel, a solid stick, an ointment or even an aerosol.
  • the cosmetic or dermatological preparation is an aqueous preparation, in particular a gel, or an emulsion, in particular an oil-in-water emulsion (O / W emulsion), since in the preparation of such preparations the advantages of the formulations according to the invention come to bear in a special way.
  • Emulsions containing the above-described formulation of the invention in or as the water phase are therefore a further subject of the present invention.
  • Particularly preferred are oil-in-water emulsion (O / W emulsion).
  • Emulsions of the invention are advantageous and contain z.
  • the lipid phase can advantageously be selected from the following substance group: - mineral oils, mineral waxes
  • Oils such as triglycerides of capric or caprylic, further natural oils such. Castor oil;
  • Fats, waxes and other natural and synthetic fats preferably esters of fatty acids with lower C-ZaN alcohols, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with low C-alkanoic acids or with fatty acids;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the context of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of from 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acid and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of from 3 to 30 carbon atoms. atoms.
  • ester oils can then be advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C-atoms.
  • the fatty acid triglycerides can be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, for. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil,
  • any mixtures of such oil and wax components are also advantageous to use in the context of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 2 -i 5 alkyl benzoate, caprylic capric triglyceride, dicapryl ether.
  • Particularly advantageous are mixtures of C 2 -1 5 alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 2 -is-alkyl benzoate and isotridecyl isononanoate and mixtures of C 2 i5-alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene are to be used advantageously in the context of the present invention.
  • the oil phase may also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or silicone oils.
  • cyclomethicone octamethylcyclotetrasiloxane
  • silicone oil to be used according to the invention.
  • Silicone oils are to be used advantageously in the context of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • mixtures of cyclomethicone and Iso tridecylisononanoat from cyclomethicone and 2-Ethylhexylisostearat.
  • the aqueous phase of the preparations according to the invention advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene - Glykolmonomethyl- or -monoethylether and analogous products, also low C-number alcohols, z.
  • alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene - Glykolmonomethyl- or -monoeth
  • isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickening agents which or which can be advantageously selected from the group of silica, aluminum silicates, polysaccharides or their derivatives, e.g. Hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageous from the group of polyacrylates, preferably a polyacrylate from the group of so-called Carbopols, for example Carbopols types 980, 981, 1382, 2984, 5984, each individually or in combination.
  • Carbopols for example Carbopols types 980, 981, 1382, 2984, 5984, each individually or in combination.
  • mixtures of the abovementioned solvents are used.
  • alcoholic solvents water can be another ingredient.
  • Emulsions according to the invention are advantageous and contain, for example, the abovementioned fats, oils, waxes and other fatty substances, as well as water and an emulsifier, as customarily used for such a type of formulation.
  • emulsifiers for example, the known W / O and O / W emulsifiers can be used. It is advantageous to use further customary co-emulsifiers in the preferred O / W emulsions according to the invention.
  • O / W emulsifiers are, for example, O / W emulsifiers, primarily from the group of substances having HLB values of 11-16, very particularly advantageously having HLB values of 14.5-15.5, provided that the O / W emulsifiers have saturated radicals R and R 1 . If the O / W emulsifiers have unsaturated radicals R and / or R 1 , or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers may also be lower or higher.
  • fatty alcohol ethoxylates from the group of ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
  • Particularly preferred are: polyethylene glycol (13) stearyl ether (steareth-13), polyethylene glycol (14) stearyl ether (steareth-14), polyethylene glycol (15) stearyl ether (steareth-15), polyethylene glycol (16) stearyl ether (steareth-16), Polyethylene glycol (17) stearyl ether (steareth-17), polyethylene glycol (18) stearyl ether (steareth-18), polyethylene glycol (19) stearyl ether (steareth-19), polyethylene glycol (20) stearyl ether (steareth-20), polyethylene glycol (12) isostearyl ether (isosteareth-12), polyethylene glycol (13) isostearyl ether (isosteareth-13), polyethylene glycol (14) - iso
  • the sodium laureth-11-carboxylate can be advantageously used.
  • the alkyl ether sulfate sodium laureth-4 sulfate can be advantageously used.
  • polyethylene glycol (30) cholesteryl ether can be advantageously used.
  • polyethylene glycol (25) soybean oil has been proven.
  • polyethylene glycol glycerol fatty acid esters from the group consisting of polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / citrate, polyethylene glycol (20 ) glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate (cocoate).
  • polyethylene glycol (20) glyceryl laurate polyethylene glycol (21) glyceryl laurate
  • polyethylene glycol (22) glyceryl laurate polyethylene glycol (23) glyceryl laurate
  • polyethylene glycol (6) glyceryl caprate / citrate polyethylene glycol (20 ) glyceryl oleate
  • sorbitan esters from the group of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • W / O emulsifiers can be used:
  • Fatty alcohols having 8 to 30 carbon atoms monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C-atoms, diglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C-atoms, monoglycerol ethers saturated and / or unsaturated , branched and / or unbranched alcohols of a
  • W / O emulsifiers are glyceryl monostearate, glyceryl, glyceryl monomyristate, glyceryl, diglyceryl monostearate, Diglycerylmonoisostearat, propylene glycol monostearate, propylene glycol monoisostearate, propylene glycol monocaprylate, propylene glycol, sorbitan, sorbitan, sorbitan, Sorbitanmonoisooleat, sucrose, cetyl alcohol, stearyl alcohol, arachidyl, behenyl, Isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyceryl mono- caprylate or PEG-30 dipolyhydroxystearate.
  • Cosmetic and dermatological preparations to be prepared according to the invention also advantageously, but not necessarily, contain inorganic pigments based on metal oxides and / or other sparingly soluble or insoluble metal compounds, in particular the oxides of titanium (T ⁇ O 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (eg MnO), aluminum (Al 2 O 3 ), cerium (eg Ce 2 O 3 ), mixed oxides of the corresponding Metals and mixtures of such oxides.
  • Particularly preferred are pigments based on " I ⁇ O 2 , and in particular micronized TiO 2 .
  • Sunscreen formulations may be composed as usual and serve the cosmetic and / or dermatological sunscreen, further for the treatment, care and cleansing of the skin and / or hair and as a make-up product in decorative cosmetics.
  • Particularly preferred according to the invention are those cosmetic and dermatological preparations which are in the form of a sunscreen.
  • these may additionally contain at least one further UVA filter and / or at least one further UVB filter and / or at least one inorganic pigment, preferably hydrophobic inorganic micropigments.
  • UV filters whose physiological harmlessness has already been demonstrated.
  • UV-A and UV-B filters there are substances known in the literature, e.g.
  • Benzylidenecamphor derivatives such as 3- (4'-methylbenzylidene) -dl-camphor (for example Eusolex 6300), 3-benzylidenecamphor (for example Mexoryl® SD), polymers of N - ⁇ (2 and 4) - [(2-oxoborn-3- ylidene) methyl] benzyl ⁇ -acrylamide (eg Mexoryl® SW), N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) anilinium methylsulfate (eg Mexoryl® SK) or (2-oxoborn-3-yl) yliden) toluene-4-sulfonic acid (eg Mexoryl® SL),
  • 3- (4'-methylbenzylidene) -dl-camphor for example Eusolex 6300
  • 3-benzylidenecamphor for example Mexoryl® SD
  • Benzoyl or dibenzoylmethanes such as 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) propane-1,3-dione (eg Eusolex® 9020) or 4-isopropyldibenzoylmethane (eg Eusolex® 8020),
  • Benzophenones such as 2-hydroxy-4-methoxybenzophenone (eg Eusolex® 4360) or 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt (eg Uvinul® MS-40),
  • Methoxycinnamic acid esters such as octyl methoxycinnamate (e.g., Eusolex®
  • 4-methoxycinnamic acid isopentyl ester e.g. as a mixture of isomers (e.g., Neo Heliopan® E 1000),
  • Salicylate derivatives such as 2-ethylhexyl salicylate (e.g., Eusolex® OS), A-isopropylbenzyl salicylate (e.g., Megasol®), or 3,3,5-trimethylcyclohexyl salicylate (e.g., Eusolex® HMS),
  • 4-aminobenzoic acid and derivatives such as 4-aminobenzoic acid, 2-ethylhexyl A- (dimethylamino) benzoate (e.g., Eusolex® 6007), ethoxylated 4-aminobenzoic acid ethyl ester (e.g., Uvinul® P25),
  • Phenylbenzimidazole sulfonic acids such as 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts (eg Eusolex® 232), 2,2- (1,4-phenylene) bisbenzimidazole-4,6-disulfonic acid or salts thereof (eg Neoheliopan® AP) or 2,2- (1,4-phenylene) bisbenzimidazole-6-sulfonic acid;
  • UV filters can be used. These organic UV filters are usually incorporated in an amount of 0.5 to 10 weight percent, preferably 1-8 wt .-%, in cosmetic formulations.
  • UV filters are also Methoxyflavone enschreibend the German patent application DE 10232595th
  • Organic UV filters are usually incorporated in an amount of 0.5 to 20 percent by weight, preferably 1-15 wt .-%, in cosmetic formulations.
  • inorganic UV filters are those from the group of titanium dioxides such as coated titanium dioxide (eg Eusolex® T-2000, Eusolex ® T-AQUA, Eusolex® T-AVO 1 ), zinc oxides (eg Sachtotec®), iron oxides or cerium oxides conceivable , These inorganic UV filters are usually incorporated in an amount of 0.5 to 20 weight percent, preferably 2-10 wt .-%, in cosmetic preparations.
  • coated titanium dioxide eg Eusolex® T-2000, Eusolex ® T-AQUA, Eusolex® T-AVO 1
  • zinc oxides eg Sachtotec®
  • iron oxides or cerium oxides conceivable
  • These inorganic UV filters are usually incorporated in an amount of 0.5 to 20 weight percent, preferably 2-10 wt .-%, in cosmetic preparations.
  • Preferred compounds having UV-filtering properties are 3- (4 '- methylbenzylidene) -dl-camphor, 1- (4-tert-butylphenyl) -3- (4-methoxy-phenyl) - pro-pan-1, 3-dione, 4-isopropyldibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, octyl methoxycinnamate, 3,3,5-trimethylcyclohexylsilylate, 4 2-Ethylhexylester (dimethylamino) benzoate, 2-ethylhexyl 2-cyano-3,3-di-phenylacrylic acid, 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanols -aminsalze.
  • the preparations according to the invention may also contain at least one photostabilizer, preferably corresponding to the formula I.
  • R 1 is selected from -C (O) CH 3 , -CO 2 R 3 , -C (O) NH 2 and -C (O) N (R 4 ) 2 ;
  • X is O or NH;
  • R 2 is 3 o-alkyl radical is a linear or branched C;
  • R 3 is a linear or branched C 1-2 o-alkyl radical, 2 Q all R 4 independently of one another are H or linear or branched C 1-6 -alkyl radicals
  • R 5 is H, a linear or branched C-. 8 -alkyl radical or a linear or branched -OCi- ⁇ -alkyl radical and R 6 is a Ci -8 -alkyl radical,
  • the photostabilizer is more preferably 2- (4-hydroxy-3,5-dimethoxybenzylidene) -malonic acid bis (2-ethylhexyl) ester.
  • the photostabilizer is more preferably 2- (4-hydroxy-3,5-dimethoxybenzylidene) -malonic acid bis (2-ethylhexyl) ester.
  • the compounds mentioned are also antioxidants.
  • antioxidants eg amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles, (eg urocaninic acid) and their derivatives, peptides such as D, L- Camosine, D-camosine, L-carnosine and their derivatives (eg anserine), carotenoids, carotenes (eg ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid), Aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, buty
  • Suitable antioxidants are also compounds of the general formulas A or B.
  • R 1 can be selected from the group -C (O) CH 3 , -CO 2 R 3 , -C (O) NH 2 and -C (O) N (R 4 ) 2 ,
  • X is O or NH
  • R 2 is linear or branched alkyl having 1 to 30 C atoms
  • R 3 is linear or branched alkyl having 1 to 20 C atoms
  • R 4 are each independently of one another H or linear or branched alkyl having 1 to 8 C atoms,
  • R 5 is linear or branched alkyl having 1 to 8 C atoms or linear or branched alkoxy having 1 to 8 C atoms and
  • R 6 denotes linear or branched alkyl having 1 to 8 C atoms, preferably derivatives of 2- (4-hydroxy-3,5-dimethoxybenzylidene) malonic acid and / or 2- (4-hydroxy-3,5-dimethoxybenzyl) - malonic acid, particularly preferably 2- (4-hydroxy-3,5-dimethoxybenzylidene) malonic acid bis- (2-ethylhexyl) ester (for example Oxynex ® ST Liquid) and / or 2- (4-hydroxy-3,5 dimethoxybenzy ) malonic acid-bis (2-ethylhexyl) ester (example RonaCare ® AP).
  • antioxidants are also suitable for use in the cosmetic preparations according to the invention.
  • Known and commercial mixtures are, for example, mixtures comprising, as active ingredients, lecithin, L - (+) - ascorbyl palmitate and citric acid (for example (for example Oxynex ® AP), natural tocopherols, L - (+) - ascorbyl palmitate, L - (+) -
  • Ascorbic acid and citric acid for example Oxynex ® K LIQUID
  • DL- ⁇ -tocopherol L - (+) -
  • Ascorbylpa faux, citric acid and lecithin eg Oxynex ® LM or
  • Butylhydroxytoluene (BHT), L - (+) - ascorbyl palmitate and citric acid e.g.
  • compositions according to the invention can be used as further ingredients
  • vitamins and vitamin derivatives selected from vitamin A, vitamin A propionate, vitamin A palmitate, vitamin A
  • vitamin Bi thiamin chloride hydrochloride
  • vitamin B 2 riboflavin
  • nicotinamide vitamin C (ascorbic acid)
  • vitamin D ergocalciferol
  • vitamin E DL- ⁇ -tocopherol
  • vitamin P active ingredient contains, in particular preferably vitamin A
  • Palmitate vitamin C and its derivatives, DL- ⁇ -tocopherol, tocopherol-E
  • Acetate, nicotinic acid, pantothenic acid and biotin Acetate, nicotinic acid, pantothenic acid and biotin.
  • the preparations according to the invention may additionally contain further customary skin-sparing or skin-care active substances.
  • these may be all active ingredients known to the person skilled in the art, such as in particular flavone derivatives, chromone derivatives, compatible solutes and other active ingredients.
  • the preparation according to the invention contains at least one repellent, the repellent preferably selected from N, N-diethyl-3-methylbenzamide, 3- (acetyl-butyl-amino) -propionic acid ethyl ester, dimethyl phthalate, butopyronoxyl, 2.3 , 4,5-bis (2-
  • the preparations according to the invention containing repellents are preferably insect repellents.
  • Insect repellents are offered in the form of solutions, gels, sticks, rollers, pump sprays and aerosol sprays, with solutions and sprays making up the bulk of commercially available products.
  • the basis for these two product forms are usually alcoholic or aqueous-alcoholic solutions with the addition of fatty substances and slight perfuming.
  • flavonoids As flavone derivatives according to the invention flavonoids and
  • the aglycones i. the sugar-free ingredients, and the
  • flavonoids Derivatives of flavonoids and aglycones understood. Furthermore, in the context of the present invention, the term flavonoid is also used Anthocyanidin (cyanidin) understood. In the context of the present invention, coumaranones are also understood as meaning their derivatives.
  • Preferred flavonoids are derived from flavanones, flavones, 3-hydroxy-flavones, aurones and isoflavones, in particular flavanones, flavones, 3-hydroxyflavones and aurones.
  • the flavonoids are preferably selected from the following compounds: 4,6,3 ', 4' -Tetrahydroxyauron, quercetin, rutin, isoquercetin, eriodictyol, taxifolin, luteolin, Trishydroxyethylquercetin (Troxequercetin) trishydroxyethylrutin (troxerutin), Trishydroxyethylisoquercetin (Troxeiso- quercetin), Trishydroxyethylluteolin (troxeluteolin), ⁇ -glycosylrutin, tiliroside and their sulfates and phosphates.
  • preferred active substances according to the invention are, in particular, rutin, tiliroside, ⁇ -glycosylrutin and troxerutin.
  • the polyphenols which are sometimes present as natural substances, are of particular interest for applications in the pharmaceutical, cosmetic or food sector.
  • the flavonoids or bioflavonoids which are mainly known as plant dyes, frequently have an antioxidant potential. Effects of the substitution pattern of mono- and dihydoxy flavones are dealt with by K. Lemanska, H. Szymusiak, B. Tyrakowska, R. Zielinski, I.M. CM. Rietjens; Current Topics in Biophysics 2000, 24 (2), 101-108. It is observed there that dihydroxyflavones having an OH group adjacent to the keto function or OH groups in the 3'4 'or 6,7 or 7,8 position have antioxidant properties, while other mono- and dihydroxyflavones are partially non-antioxidant
  • Quercetin cyanidanol, cyanidolone 1522, meletin, sophoretine, ericin, 3,3 ', 4', 5,7-pentahydroxyflavone
  • a particularly effective antioxidant eg, CA Rice-Evans, NJ Miller, G. Paganga, Trends in Plant Science 1997, 2 (4), 152-159.
  • K. Lemanska, H. Szymusiak, B. Tyrakowska, R. Zielinski, AEMF Soffers, IMCM Rietjens; Free Radical Biology & Medicine 2001, 31 (7), 869-881 investigate the pH dependence of the antioxidant action of hydroxyflavones. Quercetin shows the highest activity of the investigated structures over the entire pH range.
  • Suitable antioxidants are further compounds of the formula II
  • R 1 to R 10 may be the same or different and are selected from - H
  • R 2 , R 5 and R 6 are OH and the radicals R 1 , R 3 , R 4 and R 7 10 are H, as described in German Patent Application DE-A-10244282.
  • Chromone derivatives are preferably understood as meaning certain chromene-2-one derivatives which are suitable as active ingredients for the preventive treatment of human skin and hair against aging processes and damaging environmental influences. At the same time they show a low irritation potential for the skin, positively influence the water binding in the skin, maintain or increase the elasticity of the skin Skin and thus promote a smoothing of the skin. These compounds preferably correspond to the formula III
  • R 3 is H or straight-chain or branched C r to C 2 o-alkyl groups
  • R 4 is H or OR 8 ,
  • R 5 and R 6 may be the same or different and are selected from
  • R 7 is H, straight-chain or branched C r to C 2 o-alkyl groups, a polyhydroxy compound, such as preferably an ascorbic acid radical or glycosidic radicals and
  • the proportion of one or more compounds selected from flavonoids, Cromon derivatives and Coumaranonen in the inventive preparation is preferably from 0.001 to 5 wt .-%, particularly preferably from 0.01 to 2 wt .-% based on the total preparation.
  • Particularly preferred active ingredients are, for example, also so-called compatible solutes. These are substances that are involved in the osmoregulation of plants or microorganisms and can be isolated from these organisms. Under the generic term compatible solutes also the described in the German patent application DE-A-10133202 osmolytes are taken. Suitable osmolytes are, for example, the polyols, methylamine compounds and amino acids and in each case their precursors.
  • osmolytes are understood as meaning, in particular, substances from the group of the polyols, such as, for example, myo-inositol, mannitol or sorbitol and / or one or more of the osmolytically active substances mentioned below:
  • Precursors of these substances are, for example, glucose, glucose polymers, phosphatidylcholine, phosphatidylinositol, inorganic phosphates, Proteins, peptides and polyamic acids. Precursors are, for example, compounds that are converted into osmolytes by metabolic steps.
  • compatible substances selected from the group consisting of pyrimidinecarboxylic acids (such as ectoine and hydroxyectoine), proline, betaine, glutamine, cyclic diphosphoglycerate, N-acetylmuthine, trimethylamine N-oxide di-myo-inositol-phosphate (DIP) , cyclic 2,3-diphosphoglycerate (cDPG), 1, 1-diglycerol phosphate (DGP), ⁇ -mannosylglycerate (firoin), ⁇ -mannosylglyceramide (Firoin-A) or / and di-mannosyl-di-inositol phosphate (DMIP) or an optical isomer, derivative, eg an acid, a salt or ester of these compounds or combinations thereof.
  • pyrimidinecarboxylic acids such as ectoine and hydroxyectoine
  • proline betaine
  • glutamine cyclic diphosphoglycerate
  • ectoine (S) -1,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid) and hydroxyectoine ((S, S) -1,4,5,6-tetrahydro-5 are among the pyrimidinecarboxylic acids.
  • hydroxyectoine ((S, S) -1,4,5,6-tetrahydro-5)
  • pyrimidinecarboxylic acids stabilize enzymes and other biomolecules in aqueous solutions and organic solvents, and in particular stabilize enzymes against denaturing conditions such as salts, extreme pH, surfactants, urea , Guanidinium chloride and other compounds.
  • Ectoine and ectoine derivatives such as hydroxyectoine can be used to advantage in medicines.
  • hydroxyectoine can be used for the manufacture of a medicament for the treatment of skin diseases.
  • Other fields of use of hydroxyectoine and other ectoin derivatives are typically in areas in which, for example, trehalose is used as an additive.
  • ectoine derivatives, such as hydroxyectoine can be used as a protective substance in dried yeast and bacterial cells. Even pharmaceutical products such as non-glycosylated, pharmaceutically active peptides and proteins such as t-PA can be protected with ectoine or its derivatives.
  • European Patent Application EP-A-0 671 161 describes in particular that ectoine and hydroxyectoine are used in cosmetic preparations such as powders, soaps, surfactant-containing cleansing products, lipsticks, blushes, make-ups, skin care creams and sunscreen preparations.
  • a pyrimidinecarboxylic acid according to formula IV below is preferably used.
  • R 1 is a radical H or C 1-8 -alkyl
  • R 2 is a radical H or C 1-4 -alkyl
  • R 3 , R 4 , R 5 and R 6 are each independently a radical from the group H, OH, NH 2 and C1-4 alkyl.
  • Preference is given to using pyrimidinecarboxylic acids in which R 2 is a methyl or an ethyl group and R 1 or R 5 and R 6 are H.
  • pyrimidinecarboxylic acids ectoine ((S) -1, 4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid) and hydroxyectoine ((S, S) -1, 4,5,6- Tetrahydro-5-hydroxy-2-methyl-4-pyrimidine-carboxylic acid) used.
  • the preparations according to the invention contain such pyrimidinecarboxylic acids, preferably in amounts of up to 15% by weight.
  • the compatible solutes are selected from di-myo-inositol-phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1, 1-diglycerol-phosphate (DGP), ⁇ -mannosylglycerate (firoin), ⁇ -mannosylglyceramide (firoin-A) or / and dimannosyl-di-inositol phosphate (DMIP), ectoine, hydroxyectoine or mixtures thereof.
  • DIP di-myo-inositol-phosphate
  • cDPG cyclic 2,3-diphosphoglycerate
  • DGP 1, 1-diglycerol-phosphate
  • ⁇ -mannosylglycerate firoin
  • ⁇ -mannosylglyceramide ⁇ -mannosylglyceramide
  • DMIP dimannosyl-di-inositol phosphate
  • aryl oximes also preferably used is preferably
  • 2-hydroxy-5-methyllaurophenone oxime which is also referred to as HMLO, LPO or F5 used. Its suitability for use in cosmetic products is known for example from the German patent application DE-A-41 16 123. Preparations containing 2-hydroxy-5-methyllaurophenonoxim are therefore for
  • preparations e.g. can be used for the treatment of psoriasis, various types of eczema, irritative and toxic dermatitis, UV dermatitis and other allergic and / or inflammatory diseases of the skin and the skin appendages.
  • Preparations according to the invention which contain an aryloxime, preferably 2-hydroxy-5-methyllaurophenone oxime, show surprising anti-inflammatory suitability.
  • the preparations preferably contain from 0.01 to 10% by weight of the aryloxime, and it is particularly preferred if the preparation contains from 0.05 to 5% by weight of aryloxime.
  • the preparation according to the invention contains at least one self-tanner.
  • HC OH 2 C-OH
  • flavonoid diosmetin and its glycosides or sulfates can also be used. These compounds can be used in the form of pure substances or plant extracts.
  • diosmetin may preferably be used in the form of a chrysanthemum extract.
  • DHA 1, 3-dihydroxyacetone
  • the said self-tanner may be used alone or as a mixture. It is particularly preferred when DHA is used in admixture with another of the above-mentioned self-tanner.
  • the preparations according to the invention may also contain dyes and colored pigments.
  • the dyes and pigments can be selected from the corresponding positive list of the Cosmetics Regulation or EC List of cosmetic colorants. In most cases, they are identical to the food-approved dyes.
  • Advantageous color pigments are, for example, titanium dioxide, mica, iron oxides (for example F ⁇ 2 ⁇ 3 , F ⁇ 3 ⁇ 4 , FeO (OH)) and / or tin oxide.
  • Advantageous dyes are, for example, carmine, Berlin blue, chrome oxide green, ultramarine blue and / or manganese violet. It is particularly advantageous to choose the dyes and / or color pigments from the following list.
  • the Color Index Numbers (CIN) are taken from the Rowe Color Index, 3rd Edition, Society of Dyers and Colourists, Bradford, England, 1971.
  • the dye one or more substances from the following group: 2,4-dihydroxyazobenzene, 1 - (2'-chloro-4'-nitro-1'-phenylazo) -2-hydroxynaphthalene, Ceresrot, 2 - (4-sulfo-1 -naphthylazo) -1 -naphthol-4-sulfonic acid, calcium salt of 2-hydroxy-1,2'-azonaphthalene-1'-sulfonic acid ) calcium and barium salts of 1- (2-sulfo-4 -methyl-1-phenylazo) -2-naphthylcarboxylic acid, calcium salt of 1- (2-sulfo-1-naphthylazo) -2-hydroxynaphthalene-3-carboxylic acid, aluminum salt of 1- (4-sulfo-1- phenylazo) -2-naphthol-6-sulfonic acid, aluminum salt of 1- (4-sulfo-1- phenylazo
  • oil-soluble natural dyes e.g. Paprika extract, ß-carotene or cochineal.
  • gel creams containing pearlescent pigments are also advantageous for the purposes of the present invention.
  • types of pearlescent pigments listed below:
  • Natural pearlescent pigments e.g. , "Fish Silver” (guanine / hypoxanthine mixed crystals out
  • Monocrystalline pearlescent pigments e.g. Bismuth oxychloride (BiOCl)
  • 3rd layer substrate Pigments e.g. Mica / metal oxide
  • pearlescent pigments are, for example, pulverulent pigments or castor oil dispersions of bismuth oxychloride and / or titanium dioxide and also bismuth oxychloride and / or titanium dioxide on mica. Particularly advantageous is e.g. the luster pigment listed under CIN 77163.
  • pearlescent pigment types based on mica / metal oxide are also advantageous, for example, are the following pearlescent pigment types based on mica / metal oxide:
  • pearlescent pigments available from Merck KGaA, Darmstadt under the trade names Timiron® ®, ® or Colorona® Dichrona® ®.
  • pearlescent pigments which are advantageous in the context of the present invention are obtainable in numerous ways known per se.
  • other substrates besides mica can be coated with other metal oxides, such as silica and the like.
  • pearlescent pigments which are produced using SiO 2 .
  • Such pigments which may also additionally have goniochromatic effects are, for example under the trade name Sicopearl ® Fantastico from BASF AG, Ludwigshafen,.
  • effect pigments which are obtainable under the trade name Metasomes ® Standard / glitter in different colors (yellow, red, green, blue) from Flora Tech.
  • the glitter particles are present in mixtures with various auxiliaries and dyes (such as the dyes with the Color Index (Cl) numbers 19140, 77007, 77289, 77491).
  • the dyes and pigments can be present both individually and in a mixture and can be mutually coated with one another, wherein different coating thicknesses generally cause different color effects.
  • the total amount of dyes and coloring pigments is advantageously from the range of z. B. 0.1 wt .-% to 30 wt .-%, preferably from 0.5 to 15 wt .-%, in particular from 1, 0 to 10 wt .-%, each based on the total weight of the preparations.
  • compositions are either known and commercially available or may be synthesized by known methods. Any customary carrier substances, adjuvants and optionally further active ingredients can be added to the preparation. Preferable excipients come from the group of preservatives, antioxidants, stabilizers, solubilizers, vitamins, colorants, odor improvers.
  • Solutions and emulsions may contain the usual excipients such as solvents, solubilizers and emulsifiers, e.g. Water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerin fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures contain these substances.
  • solvents e.g. Water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil,
  • the preparations according to the invention contain hydrophilic surfactants.
  • the hydrophilic surfactants are preferably selected from the group of alkylglucosides, acyl lactylates, betaines and cocoamphoacetates.
  • the alkylglucosides in turn are advantageously selected from the group of alkylglucosides, which are represented by the structural formula
  • R represents a branched or unbranched alkyl radical having 4 to 24 carbon atoms and wherein DP means a mean Glucosyl michsgrad of up to 2.
  • DP represents the degree of glucosidation of the alkylglucosides used in the invention and is defined as
  • pi, p 2) P 3 ••• or p ⁇ represent the proportion of single, double-triple ... times glucosylated products in weight percent.
  • the value of DP takes account of the fact that alkylglucosides, as a rule, are mixtures of mono- and oligoglucosides.
  • Advantageously in accordance with the invention is a relatively high content of monoglucosides, typically of the order of 40-70% by weight.
  • Alkylglylcosides used with particular advantage are selected from the group consisting of octylglucopyranoside, nonylglucopyranoside, decylglucopyranoside, undecylglucopyranoside, dodecylglucopyranoside, tetradecylglucopyranoside and hexadecylglucopyranoside.
  • acyl lactylates are advantageously selected from the group of substances which are defined by the structural formula
  • R 1 is a branched or unbranched alkyl radical having 1 to 30 carbon atoms and M + is selected from the group of the alkali metal ions and the group of ammonium ions substituted by one or more alkyl and / or by one or more hydroxyalkyl radicals or half Equivalent to an alkaline earth metal equivalent.
  • sodium isostearyl lactylate for example, is advantageous
  • R 2 is a branched or unbranched alkyl radical having 1 to 30 carbon atoms.
  • R 2 is a branched or unbranched alkyl radical having 6 to 12 carbon atoms.
  • capramidopropylbetaine for example the product Tego ® betaine 810 from Th. Goldschmidt AG.
  • AIs invention advantageous cocoamphoacetate, sodium is selected, for example, as under the name Miranol ® Ultra C32 from Miranol Chemical Corp. is available.
  • the preparations according to the invention are advantageously characterized in that the hydrophilic surfactant or surfactants in concentrations of 0.01-20 wt .-%, preferably 0.05-10 wt .-%, particularly preferably 0.1-5 wt .-%, respectively based on the total weight of the composition, is present or present.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics.
  • the preparation may contain cosmetic adjuvants which are commonly used in this type of preparations, e.g.
  • Thickening agents emollients, humectants, surfactants, emulsifiers, preservatives, antifoaming agents, perfumes, waxes, lanolin, propellants, dyes and / or pigments which color the agent itself or the skin, and other ingredients commonly used in cosmetics.
  • dispersion or solubilizing agent an oil, wax or other fatty substance, a low monoalcohol or a low polyol or mixtures thereof.
  • Particularly preferred monoalcohols or polyols include ethanol, i-propanol, propylene glycol, glycerine and sorbitol.
  • a preferred embodiment of the invention is an emulsion which is present as a protective cream or milk and contains, for example, fatty alcohols, fatty acids, fatty acid esters, in particular triglycerides of fatty acids, lanolin, natural and synthetic oils or waxes and emulsifiers in the presence of water.
  • a preferred embodiment are also hydrogels.
  • the customary propellants such as alkanes, fluoroalkanes and chlorofluoroalkanes, are generally used.
  • the cosmetic preparation can also be used to protect the hair against photochemical damage to changes of
  • Shades of color to prevent discoloration or damage of a mechanical nature is suitably carried out as a shampoo, lotion, gel or emulsion for rinsing, wherein the respective preparation before or after shampooing, before or after dyeing or decolorization or before or after the permanent wave is applied. It is also possible to choose a preparation as a lotion or gel for hairdressing and treatment, as a lotion or gel for brushing or laying a wave of water, as hair lacquer, perming agent, dyeing or decolorizing the hair.
  • the photoprotective composition may contain various adjuvants used in this medium type, such as surfactants, thickeners, polymers, emollients, preservatives, foam stabilizers, electrolytes, organic solvents, silicone derivatives, oils, waxes, anti-grease agents, dyes and / or pigments the agent itself or the hair dye or other commonly used for hair care ingredients.
  • adjuvants used in this medium type such as surfactants, thickeners, polymers, emollients, preservatives, foam stabilizers, electrolytes, organic solvents, silicone derivatives, oils, waxes, anti-grease agents, dyes and / or pigments the agent itself or the hair dye or other commonly used for hair care ingredients.
  • the preparations according to the invention contain further UV filter substances, the total amount of filter substances being e.g. 0.1 to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular 1 to 6 wt .-%, based on the total weight of the preparations.
  • preparations according to the invention can also be used as pharmaceutical agents for the preventive treatment of inflammation and allergies of the skin as well as in certain cases for the prevention of certain cancers.
  • the pharmaceutical agent of the invention may be administered orally or topically.
  • the preparations of the invention may be prepared by techniques well known to those skilled in the art. Even without further explanation, it is assumed that a person skilled in the art can make the most of the above description. The preferred embodiments are therefore to be considered as merely illustrative, and not in any way limiting, disclosure. The following examples are intended to illustrate the present invention without limiting it. Unless indicated otherwise, all amounts, proportions and percentages are based on the weight and the total amount or the total weight of the preparations. The complete disclosure of all applications and publications cited above and below are incorporated by reference into this application. In these examples, the preferred compound of formula I is the N-dimethyldecanamide Spectrasolv DMDA (Jiangsu Feixang Chemicals or Lehmann & Voss). The preferred sparingly soluble organic UV filter is ethylhexyl triazone.
  • the particle size determination is carried out by laser diffraction according to ISO / DIS
  • Dispersing medium water
  • Refractive index dispersing medium 1, 33
  • UV APF in vitro (UV) APF was determined according to the German standard DIN 67502, "Characterization of the UVA protective effect of dermal sunscreens by transmission measurements taking into account the sun protection factor", 3rd standard template, March 2003.
  • a solution of 400 g of ethylhexyl triazone, 400 g of dimethyl capramide (Spectrasolv DMDA) and 240 g of tetraethyl orthosilicate is emulsified with cooling with the aid of an emulsifying tool (Ultra Turax) in a surfactant solution [448 g of deionized water and 11 g of cetyltrimethylammonium chloride (CTAC)].
  • CTAC cetyltrimethylammonium chloride
  • the finished emulsion is added to hydrochloric acid with stirring. The resulting mixture is stirred for 48-72 h at room temperature. Thereafter, the hydrolysis of the Alkylsilanes resulting ethanol depleted by distillation.
  • the pH of the residue is adjusted to 3.4-3.6 with Na citrate solution and made up to completion with demineralized water.
  • the active ingredient content of the suspension is 18% by weight.
  • the incorporation into the cosmetic preparation can take place in this form.
  • the isolation of the silica capsule is possible by conventional methods.
  • UV filter capsules were prepared with solvents known in the market.
  • test substance is in small beakers on a heatable magnetic stirrer in the solvent (eg cosmetic Emollient, as indicated in the table) with stirring first at room temperature (about 2O 0 C - 25 0 C) incorporated (the stirring time should about 30 min do not exceed).
  • solvent eg cosmetic Emollient, as indicated in the table
  • stirring time should about 30 min do not exceed.
  • the assessment is done visually, ie it is checked whether a completely clear solution and without recognizable particles is present. Used quantities, conditions and stirring times are to be noted. If the substance is well soluble, the concentration will be delayed
  • the evaluation is carried out, for example, with Agilent HPLC ChemStation; i.e. the peak areas are evaluated according to the external standard evaluation method.
  • a solution of 240 g of bis-ethylhexyloxyphenol methoxyphenyl triazine, 560 g of dimethyl capramide (Spectrasolv DMDA) and 240 g of tetraethyl orthosilicate is added with cooling by means of an emulsifying tool (Ultra Turax) in a surfactant solution [448 g demineralized water and 11 g cetyltrimethylammonium chloride (CTAC)] emulsified.
  • CTAC cetyltrimethylammonium chloride
  • the pH of the residue is adjusted to 3.4-3.6 with Na citrate solution and made up to completion with demineralized water.
  • the active ingredient content of the suspension is 10.8 wt .-%.
  • the incorporation into the cosmetic preparation can take place in this form.
  • the isolation of the silica capsule is possible by conventional methods.
  • phase A except for Carbopol and dissolve Eusolex® 9020. If necessary, warm to approx. 50 ° C. Incorporate Carbopol and emulsify pre-dissolved phase B with stirring. Homogenize. Homogenise briefly after adding phase C.
  • Phase A is combined, without Eusolex® T-2000 and heated to 80 0 C. Thereafter, Eusolex® T-2000 is slowly added to the hot oil phase with stirring. Phase B is prepared and heated to 75 ° C. After that will
  • Phase B slowly to Phase A with stirring. Homegenizing and cooling. Under 35 0 C Phase C is added.
  • Emulsion 1 Emulsion 2 with 2% ethylhexyl with 4% triazone ethylhexyl [%] triazone [%]
  • Eumulgin VL 75 Lauryl Glucoside, 4.00 4.00 Polyglyceryl-2-dipolyhydroxystearates, glycerol
  • UV filter Aqua water
  • phase B Combine phase B and also heat to 80 ° C. Emulsify phase B in phase A with stirring and homogenize for 3 min. Cool with stirring, adjusted with citric acid pH and incorporated at about 30 0 C Eusolex® UV-Pearls TM Uvinul T 150 and preservatives.
  • Tinosorb S BIS-ETHYLHEXYLOXYPHENOL 2.00 5.00
  • Soya oil GLYCINE SOY (SOYBEAN OIL) 5,00 12,50 RonaCare® TOCOPHERYL ACETATE 1, 00 2,50 tocopherol
  • phase A except Carbopol and dissolve Tinosorb S. If necessary, warm to approx. 60 ° C.
  • Phase A is combined with stirring, without Eusolex® T-2000 and heated to 80 0 C until Tinosorb S is dissolved. Thereafter, Eusolex® T-2000 is slowly added to the hot oil phase with stirring.
  • Phase B is prepared and heated to 75 ° C. Thereafter, phase B is slowly added with stirring to phase A. Homegenizing and cooling. Below 35 ° C, Phase C is added.
  • Tinosorb S BIS-ETHYLHEXYLOXYPHENOL 2.00 5.00
  • Phase B Disperse Keltrol in water. Add the remaining ingredients and mix.
  • the fundamental measuring principle on which the measurement is based is the
  • the preparation is applied to a suitable substrate in a defined layer thickness and measured on a suitable UV photometer in nanometer increments, the absorption.
  • the in vitro sun protection factor is calculated according to the following formula:
  • Substrate PMMA plexiglass plate, type XT220070 in size 7.5 cm x 2.5 cm (Roehm, Darmstadt), roughened on one side by means of sand blasting (90-150 ⁇ m glass beads, 30 bar, 30 cm distance). Specification: DIN 67502
  • Sample preparation As many small droplets as possible to be determined
  • Sample are applied to the substrate with a suitable pipette or spatula and distributed homogeneously.
  • a suitable pipette or spatula In this case, the tara of the substrate, the order quantity in the wet state and after equilibration
  • Each sample is measured on at least three substrates.
  • UV photometric e.g., Cary 300 Bio (Varian Inc. Paolo Alto, USA) with integrating sphere (Labsphere
  • Example D 4.5.
  • Example 6 Determination of SPF value in vivo according to COLIPA (International Sun Protection Factor (SPF) Test Method, COLIPA, Mav 2006)
  • UV Source 300 Watt Xenon Arc Lamp Sun Simulator (Model 601-300 Multiport, Solar Light Co. Inc. Inc. Philadelphia, PA, USA)
  • the main test is performed on 35 cm 2 large areas of the back.
  • each test area is divided into 6 zones. Each zone is exposed to a different dose of radiation.
  • the irradiation times for the individual test subjects are determined on the basis of the individual MED values determined in the pre-tests. The evaluation is carried out 16-24 hours after irradiation by trained personnel.
  • phase A The components of phase A are heated to 80 ° C.
  • phase B The components of phase B are dispersed at room temperature with stirring and added to the phase A.
  • phase C The components of phase C are homogenized and added to the
  • phase A Added mixture of phases A and B and homogenized again.
  • the components of phases D and E are added to the mixture of phases A + B + C, homogenized again and then cooled to room temperature.
  • Viscosity 42600 mPas pH: 6.5
  • phase A The components of phase A are heated to 80 ° C.
  • phase B The components of phase B are dispersed at room temperature with stirring and added to the phase A.
  • phase C The components of phase C are homogenized and added to the
  • phase A Added mixture of phases A and B and homogenized again.
  • the components of phases D and E are added to the mixture of phases A + B + C, homogenized again and then cooled to room temperature.
  • Viscosity 3450 mPas pH value: 6.5
  • phases A and B are each heated separately to 80 0 C, then added together and briefly homogenized.
  • the mixture is cooled to 40 0 C and homogenized again.
  • phase C component is added to the mixture of phases A and B and all homogenized together.
  • Viscosity (Brookfield SP6): 3350 mPas pH: 7.0
  • phases A and B are each heated separately to 8O 0 C, then added together and homogenized for a short time.
  • phase C are added to the mixture of phases A and
  • phase D The mixture is cooled to 40 c C, and homogenized again.
  • the components of phase D are added to the mixture of phases A + B + C and all homogenized together.
  • Viscosity (Brookfield SP6): 7450 mPas pH: 7.3
  • Viscosity (Brookfield SP6): 3350 mPas pH-value: 7.0
  • Formulation 8 O / W emulsion
  • Viscosity (Brookfield SP6): 7450 mPas pH-value: 7.3
  • phase B Add phase B to the molten phase A and homogenize.
  • phase B Add phase B to the molten phase A and homogenize.
  • phase D briefly homogenize and cool to room temperature while stirring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des capsules filtrant les UV, leur utilisation pour la production de formulations ou de dispersions cosmétiques ou dermatologiques, des formulations cosmétiques ou dermatologiques contenant ces capsules, ainsi que des procédés de production associés.
PCT/EP2008/005408 2007-07-26 2008-07-02 Capsule filtrant les uv WO2009012871A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/670,442 US20100209463A1 (en) 2007-07-26 2008-07-02 Uv filter capsule
KR1020107004187A KR101529341B1 (ko) 2007-07-26 2008-07-02 Ｕｖ 필터 캡슐
ES08773820.9T ES2522909T3 (es) 2007-07-26 2008-07-02 Cápsula filtrante de radiación UV
EP08773820.9A EP2170253B1 (fr) 2007-07-26 2008-07-02 Capsule filtrant les uv
JP2010517286A JP2010534623A (ja) 2007-07-26 2008-07-02 Ｕｖフィルターカプセル
CN2008801004407A CN101795662B (zh) 2007-07-26 2008-07-02 Uv过滤剂胶囊
BRPI0814313A BRPI0814313B1 (pt) 2007-07-26 2008-07-02 cápsula de filtro uv, sua dispersão, seu uso, composição e processos para preparação da dita cápsula e dita composição
US15/395,013 US20170105910A1 (en) 2007-07-26 2016-12-30 Uv filter capsule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007035567.1 2007-07-26
DE102007035567A DE102007035567A1 (de) 2007-07-26 2007-07-26 UV-Filter-Kapsel

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/670,442 A-371-Of-International US20100209463A1 (en) 2007-07-26 2008-07-02 Uv filter capsule
US15/395,013 Continuation US20170105910A1 (en) 2007-07-26 2016-12-30 Uv filter capsule

Publications (2)

Publication Number Publication Date
WO2009012871A2 true WO2009012871A2 (fr) 2009-01-29
WO2009012871A3 WO2009012871A3 (fr) 2010-01-28

Family

ID=39811779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/005408 WO2009012871A2 (fr) 2007-07-26 2008-07-02 Capsule filtrant les uv

Country Status (9)

Country Link
US (2) US20100209463A1 (fr)
EP (1) EP2170253B1 (fr)
JP (2) JP2010534623A (fr)
KR (1) KR101529341B1 (fr)
CN (1) CN101795662B (fr)
BR (1) BRPI0814313B1 (fr)
DE (1) DE102007035567A1 (fr)
ES (1) ES2522909T3 (fr)
WO (1) WO2009012871A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003774A2 (fr) 2009-07-07 2011-01-13 Basf Se Combinaisons de filtres anti-uv contenant des malonates de benzylidène
WO2011131644A1 (fr) 2010-04-20 2011-10-27 Basf Se Capsule comprenant un ingrédient actif
TWI454310B (zh) * 2009-12-24 2014-10-01 Kao Corp Water particles and its manufacturing methods, and anti-ultraviolet cosmetics
US10449135B2 (en) 2014-04-09 2019-10-22 Basf Se Solublizing agents for UV filters in cosmetic formulations
US11046814B2 (en) 2016-10-05 2021-06-29 Basf Se Ultraviolet radiation absorbing polymer composition
US11793742B2 (en) 2014-04-11 2023-10-24 Basf Se Mixtures of cosmetic UV absorbers

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009044891A1 (de) 2009-12-14 2011-06-16 Gabriele Dr. Blume Trägersystem zum Einschließen lipophiler Wirkstoffe und Öle in hoher Konzentration
DE102011076149A1 (de) * 2011-05-19 2012-11-22 Rovi Cosmetics International Gmbh Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare
CN102274229A (zh) * 2011-09-01 2011-12-14 朱道辰 一种治疗皮炎的外用药物及其制法
US9549891B2 (en) 2012-03-19 2017-01-24 The Procter & Gamble Company Superabsorbent polymers and sunscreen actives for use in skin care compositions
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
WO2014165434A2 (fr) * 2013-04-02 2014-10-09 Basf Se Pièces en plastique renforcées par des fibres de carbone revêtues
JP6802160B2 (ja) * 2014-12-04 2020-12-16 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ マイクロカプセル
KR102618836B1 (ko) * 2014-12-09 2023-12-28 바스프 에스이 화장품 제제에서의 uv 필터를 위한 가용화제
CA2988808C (fr) 2015-06-29 2021-05-25 The Procter & Gamble Company Polymeres, cires, huiles et poudres d'amidon superabsorbants destines aux compositions de soins de la peau
GB201520301D0 (en) * 2015-11-18 2015-12-30 Tan Safe Ltd Sun protective compositions
DE102018203496A1 (de) * 2018-03-08 2019-09-12 Beiersdorf Ag Sonnenschutzmittel mit reduzierter Textilverfleckung enthaltend hydriertes Pflanzenöl und Diethylamino Hydroxybenzoyl Hexyl Benzoate
DE102020204937A1 (de) * 2020-04-20 2021-10-21 Beiersdorf Aktiengesellschaft Umweltfreundliches Sonnenschutzmittel
CN114149339B (zh) * 2021-12-28 2023-01-31 黄冈美丰化工科技有限公司 一种紫外线吸收剂、组合物、化妆品及配制化妆品的工艺

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009652A2 (fr) 1998-08-13 2000-02-24 Sol-Gel Technologies Ltd. Procede de preparation de microcapsules d'oxyde chargees avec des molecules fonctionnelles et produits obtenus a partir desdites microcapsules d'oxyde
WO2000071084A1 (fr) 1999-05-25 2000-11-30 Sol-Gel Technologies Ltd Procede pour obtenir des compositions de protection solaire photostables
WO2000072806A2 (fr) 1999-05-26 2000-12-07 Sol-Gel Technologies Ltd Compositions de filtres solaires contenant des microcapsules sol-gel
US6242099B1 (en) 1996-11-21 2001-06-05 Merck S.A. Microcapsules made of chitin or of chitin derivatives containing a hydrophobic substance, in particular a sunscreen, and process for the preparation of such microcapsules
WO2003039510A1 (fr) 2001-11-08 2003-05-15 Sol-Gel Technologies Ltd. Compositions contenant des huiles presentant une densite plus elevee que la densite de l'eau
WO2003066209A1 (fr) 2002-02-07 2003-08-14 Dow Corning Corporation Procede d'encapsulation et compositions encapsulees

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL190101C (nl) 1978-11-13 1993-11-01 Givaudan & Cie Sa Dibenzoylmethaanverbinding en tegen licht beschermend preparaat.
DE3206398A1 (de) 1982-02-23 1983-09-01 Basf Ag, 6700 Ludwigshafen S-triazinderivate und ihre verwendung als lichtschutzmittel
DE4116123B4 (de) 1991-05-17 2006-03-09 Merck Patent Gmbh Mittel zur Behandlung von Hauterkrankungen
DE4342560A1 (de) 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
JPH07267841A (ja) * 1994-03-31 1995-10-17 New Oji Paper Co Ltd 化粧料
FR2727861B1 (fr) * 1994-12-12 1997-01-17 Oreal Procede de photostabilisation de filtres solaires derives du dibenzoylmethane, compositions cosmetiques filtrantes photostabilisees ainsi obtenues et leurs utilisations
IT1283295B1 (it) 1996-03-22 1998-04-16 3V Sigma Spa Filtri solari
IT1289511B1 (it) 1996-12-23 1998-10-15 3V Sigma Spa Soluzioni concentrate di filtro solare derivato della 1,3,5- triazina e loro uso per la preparazione di composizioni cosmetiche
EP0916335B1 (fr) 1997-08-13 2004-11-03 Basf Aktiengesellschaft Compositions cosmétiques et pharmaceutiques contenant un filtre UV photostabile
DE19828463A1 (de) * 1998-06-26 1999-12-30 Basf Ag 4,4-Diarylbutadiene als wasserlösliche photostabile UV-Filter für kosmetische und pharmazeutische Zubereitungen
DE50115609D1 (de) * 2000-02-17 2010-10-14 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
DE10133202A1 (de) 2001-07-07 2003-01-16 Beiersdorf Ag Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
EP1952843B1 (fr) 2001-07-16 2011-07-27 Merck Patent GmbH Composés d'écran solaire organique photostable ayant des propriétés antioxydantes et compositions ainsi obtenues
US6770270B2 (en) * 2002-03-05 2004-08-03 The C.P. Hall Company Methods of making and selling a sunscreen composition
US6485713B1 (en) * 2002-03-05 2002-11-26 The C. P. Hall Company Sunscreen compositions and methods and materials for producing the same
US6537529B1 (en) * 2002-03-05 2003-03-25 The C.P. Hall Company Sunscreen compositions and methods and materials for producing the same
US20030215472A1 (en) * 2002-05-16 2003-11-20 Bonda Craig A Methods and compositions employing a dialkyl amide
DE10232595A1 (de) 2002-07-18 2004-02-05 Merck Patent Gmbh Lichtschutzmittel
DE10244282A1 (de) 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
JP2004168913A (ja) * 2002-11-20 2004-06-17 Shiseido Co Ltd 紫外線吸収性複合粉体
US20040228811A1 (en) * 2003-05-13 2004-11-18 Kimberly-Clark Worldwide, Inc. Sunscreen wipes having high sunscreen formulation transfer rate
BRPI0413131A (pt) * 2003-07-31 2007-04-10 Sol Gel Technologies Ltd micro-cápsulas carregadas com ingredientes ativos e um método para sua preparação
KR20070108389A (ko) * 2005-01-31 2007-11-09 아케아 사이언티픽 코포레이션 바디워시를 위한 첨가제
US7001592B1 (en) * 2005-01-31 2006-02-21 Aquea Scientific Corporation Sunscreen compositions and methods of use
WO2007085568A1 (fr) * 2006-01-27 2007-08-02 Basf Se Utilisation de n,n-diméthyldécanamide dans des préparations cosmétiques
DE102006006413A1 (de) * 2006-02-13 2007-08-23 Merck Patent Gmbh UV-Filter-Kapsel

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242099B1 (en) 1996-11-21 2001-06-05 Merck S.A. Microcapsules made of chitin or of chitin derivatives containing a hydrophobic substance, in particular a sunscreen, and process for the preparation of such microcapsules
WO2000009652A2 (fr) 1998-08-13 2000-02-24 Sol-Gel Technologies Ltd. Procede de preparation de microcapsules d'oxyde chargees avec des molecules fonctionnelles et produits obtenus a partir desdites microcapsules d'oxyde
WO2000071084A1 (fr) 1999-05-25 2000-11-30 Sol-Gel Technologies Ltd Procede pour obtenir des compositions de protection solaire photostables
WO2000072806A2 (fr) 1999-05-26 2000-12-07 Sol-Gel Technologies Ltd Compositions de filtres solaires contenant des microcapsules sol-gel
WO2003039510A1 (fr) 2001-11-08 2003-05-15 Sol-Gel Technologies Ltd. Compositions contenant des huiles presentant une densite plus elevee que la densite de l'eau
WO2003066209A1 (fr) 2002-02-07 2003-08-14 Dow Corning Corporation Procede d'encapsulation et compositions encapsulees

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003774A2 (fr) 2009-07-07 2011-01-13 Basf Se Combinaisons de filtres anti-uv contenant des malonates de benzylidène
TWI454310B (zh) * 2009-12-24 2014-10-01 Kao Corp Water particles and its manufacturing methods, and anti-ultraviolet cosmetics
WO2011131644A1 (fr) 2010-04-20 2011-10-27 Basf Se Capsule comprenant un ingrédient actif
JP2013531614A (ja) * 2010-04-20 2013-08-08 ビーエーエスエフ ソシエタス・ヨーロピア 活性成分を含むカプセル
US10449135B2 (en) 2014-04-09 2019-10-22 Basf Se Solublizing agents for UV filters in cosmetic formulations
US11793742B2 (en) 2014-04-11 2023-10-24 Basf Se Mixtures of cosmetic UV absorbers
US11046814B2 (en) 2016-10-05 2021-06-29 Basf Se Ultraviolet radiation absorbing polymer composition

Also Published As

Publication number Publication date
CN101795662B (zh) 2013-01-02
EP2170253B1 (fr) 2014-09-24
JP2015003934A (ja) 2015-01-08
JP5869087B2 (ja) 2016-02-24
WO2009012871A3 (fr) 2010-01-28
KR20100052489A (ko) 2010-05-19
US20100209463A1 (en) 2010-08-19
CN101795662A (zh) 2010-08-04
EP2170253A2 (fr) 2010-04-07
ES2522909T3 (es) 2014-11-19
US20170105910A1 (en) 2017-04-20
JP2010534623A (ja) 2010-11-11
KR101529341B1 (ko) 2015-06-16
BRPI0814313B1 (pt) 2017-04-04
DE102007035567A1 (de) 2009-01-29
BRPI0814313A2 (pt) 2016-10-11

Similar Documents

Publication Publication Date Title
EP2170253B1 (fr) Capsule filtrant les uv
EP1660592B1 (fr) Agent anti-uv nanoparticulaire pourvu d'un revetement de dioxyde de silicium
EP1848507B1 (fr) Composition contenant un agent anti-uv nanoparticulaire
EP1763383B1 (fr) Particule fonctionnalisee avec des composes organiques
EP1720510B1 (fr) Filtre uv sous forme de poudre
WO2005074897A2 (fr) Auxiliaires de formulation
EP2004136B1 (fr) Utilisation de flavonoïdes
WO2007093252A1 (fr) Capsule de filtre anti-uv contenant une hydroxybenzophénone aminosubstituée
DE102005013380A1 (de) Extraktionsverfahren
WO2007014614A1 (fr) Procede de bronzage
DE102005047647A1 (de) a,a'-Dihydroxyketonderivate und deren Verwendung als UV-Filter
DE102004011111A1 (de) Formulierung zur Stabilisierung von UV-Filtern
EP1846429A2 (fr) Complexes de flavonoïdes comprenant des cyclodextrines
DE102007041854A1 (de) Bifunktionelle DHA-Derivate
DE102004045482A1 (de) UV-Filter-Mischung
WO2007065524A1 (fr) Ester d’erythrulose en tant que filtre uv
DE102004025372A1 (de) Verwendung von Effektpigmenten

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880100440.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08773820

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008773820

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12670442

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010517286

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 666/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107004187

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0814313

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100125